Can three existing drugs protect nerves from damage in MS?

Dr Jeremy Chataway, lead researcher

Dr Jeremy Chataway

UCL Institute of Neurology

Funded by an MRC and NIHR partnership, and the MS Society.

We contributed £300,000.
 

About the project

We’re proud to be co-funding this innovative phase 2 trial, which will test three potential treatments for secondary progressive MS.

The trial will run for three years and test the benefits of amiloride, fluoxetine and riluzole against a placebo. All three drugs are already used to treat other conditions.

MS-SMART will involve 440 people with secondary progressive MS. Our researchers will use MRI scans to test if any of the drugs could protect nerves from damage in MS. They will do this by measuring if the drugs slow the rate of brain atrophy (shrinkage).

The trial is due to finish in 2018.

How will it help people with MS?

Right now there are no treatments that can slow or stop the accumulation of disability in secondary progressive MS. This trial will help to identify promising drugs that can be tested in phase 3 trials.
 

The difference you can make

The race is on to find therapies that will slow progression. You can help speed up the process by supporting projects like this.

>> Donate now to fund vital MS research
 

What's new?